Development of chitosan coated calcium-alginate nanocapsules for oral delivery of liraglutide to diabetic patients.
Int J Biol Macromol · 2018
Last updated 2026-05-28Researchers developed tiny capsules coated with chitosan and calcium-alginate to deliver the diabetes drug liraglutide by mouth. The most effective capsules were about 100 nanometers wide, held 92.5% of the drug, and released 59.1% of it over 6 hours in lab tests. The capsules remained stable at 4°C for 60 days, losing only 27.7% of their structure. The study suggests these natural, biodegradable capsules could be a promising way to deliver liraglutide orally for diabetes management.
AI summary of the abstract below.
| Journal | Int J Biol Macromol, 2018 |
|---|---|
| Citations | 33 |
| Relative citation ratio | 1.88 |
| NIH percentile | 72 |
| Molecules | liraglutide |
| Conditions studied | Type 2 Diabetes |
Abstract
Chitosan coated calcium-alginate nanocapsules were developed for oral sustained delivery of liraglutide. The effect of coating components including sodium alginate, calcium chloride, and chitosan concentrations on the particle size was studied based on response surface methodology. The beads were characterized by dynamic light scattering, scanning and transmission electron microscopy as well as Fourier transform infrared spectroscopy. It was shown that the diameter of the formed beads was most dependent on the encapsulation technique and alginate concentration. SEM revealed spherical and smooth particles of up to 100 nm diameter for the optimum composition of alginate 0.5%, chitosan 0.5% and calcium chloride 0.5% in the volume ratio of 3:1:1. The resulting bead formulation had a loading efficiency of 92.5% and loading capacity of 54.16%. The nanocapsules exhibited stability of 92.4% and 72.3% over freeze drying and subsequent 60 days storage at 4 °C, respectively. In-vitro release studies in simulated gastrointestinal conditions were carried out in a sequential technique and the amount of drug release was found to be 59.1% after 6 h. The results of this study demonstrated that chitosan coated calcium-alginate nanocapsules hold promise as a potential natural biodegradable polymer-based oral carrier of liraglutide for better management of diabetes.
Verbatim abstract via PubMed 30125628 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.